Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior…
Read More: https://www.globenewswire.com/news-release/2024/06/17/2899307/0/en/HUTCHMED-Highlights-Publication-of-Phase-III-ESLIM-01-Results-in-The-Lancet-Haematology.html
Stay updated with the latests analysis and insights fromm etfsector.com